Skip to main content
Clinical Trials/JPRN-UMIN000032665
JPRN-UMIN000032665Recruiting未知

The efficacy and the utility of switching into glucagon like peptide-1 receptor agonist plus basal insulin therapy in type 2 diabetic patients treated with Basal-Bolus therapy. - The efficacy and the utility of switching from basal-bolus therapy to GLP-1 RA plus basal insulin therapy.

Department of Endocrinology, Nippon Medical School Chiba Hokusoh Hospital0 sites100 target enrollmentStarted: May 21, 2018Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Recruiting
Sponsor
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to 75years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Type 1 diabetes with severe liver disease, severe renal disease or severe heart disease with any carcinoma under pregnancy

Investigators

Sponsor
Department of Endocrinology, Nippon Medical School Chiba Hokusoh Hospital

Similar Trials